US · EWTX
Edgewise Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boulder, CO 80303
- Website
- edgewisetx.com
Price · as of 2025-12-31
$30.61
Market cap 3.22B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $11.22 | ||||
| 2022 | $7.41 | ||||
| 2023 | $17.16 | ||||
| 2024 | $28.01 | ||||
| 2025 | $29.70 |
AI valuation
Our deep-learning model estimates Edgewise Therapeutics, Inc.'s (EWTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $30.61
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EWTX | Edgewise Therapeutics, In… | $30.61 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| CLDX | Celldex Therapeutics, Inc… | $30.09 | 2B | +2% | -54% | — | +767% | -7.71 | 3.78 | 1330.00 | -5.79 | -13.03 | 3.99 | 100.00% | -19160.00% | -17253.33% | -40.62% | -1576.31% | -37.63% | 0.00 | — | 10.49 | 10.21 | 0.10 | 5918.00% | -7863.00% | 3379.00% | -10.71% | -4.14 | -1171.86% | 0.00% | 0.00% | 0.10% | -5.15 | -6.92 | 985.84 | 16.46 |
| GLPG | Galapagos N.V. | $33.66 | 2.22B | +251% | +430,280% | +154% | +4,930% | 6.01 | 0.60 | 1.73 | -1.90 | 1.80 | 0.60 | 93.49% | 40.56% | 28.85% | 10.47% | 2205.83% | 8.51% | 0.00 | 164.04 | 20.15 | 19.95 | -0.14 | 33304.00% | 30348.00% | -4967.00% | -10.50% | -1.24 | -989.65% | 0.00% | 0.00% | 1.20% | -2.34 | 5.22 | -0.95 | 8.66 |
| GPCR | Structure Therapeutics In… | $62.98 | 3.63B | — | — | — | — | -26.37 | 2.46 | — | -16.39 | -1028.46 | 2.46 | 0.00% | — | — | -11.86% | -570.89% | -11.35% | 0.00 | — | 24.81 | 22.85 | 5.69 | 256.00% | — | 9149.00% | -6.06% | -3.51 | -730.15% | 0.00% | 0.00% | 16.85% | -12.94 | -10.11 | — | 33.44 |
| JANX | Janux Therapeutics, Inc. | $13.61 | 818.61M | +171% | -7% | -80% | — | — | 0.87 | 83.16 | 0.99 | — | 0.87 | 79.71% | -1576.67% | -1576.67% | 0.00% | -954.78% | 0.00% | 0.02 | — | 39.04 | 38.67 | 0.27 | 4297.00% | -555.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 0.00% | 0.72 | — | -11.28 | 11.29 |
| MESO | Mesoblast Limited | $15.85 | 2.04B | +203% | -57% | — | — | -17.02 | 2.91 | 101.06 | -23.15 | — | 67.85 | 70.17% | -363.08% | -593.92% | -18.95% | -11.34% | -14.05% | 0.21 | -2.72 | 1.99 | 1.72 | 0.45 | -562.00% | 19139.00% | 388.00% | -2.92% | -0.49 | -9.21% | 0.00% | 0.00% | 5.14% | -27.31 | -33.64 | 99.14 | 3.68 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| OCUL | Ocular Therapeutix, Inc. | $8.94 | 1.95B | +214% | -39% | — | +53% | -7.73 | 3.14 | 39.67 | -5.60 | -47.16 | 3.14 | 87.31% | -521.04% | -513.17% | -54.85% | 13699.49% | -42.01% | 0.12 | -22.82 | 15.39 | 15.11 | 2.63 | 1639.00% | -1867.00% | 5952.00% | -10.55% | -4.03 | 11004.21% | 0.00% | 0.00% | 16.58% | -5.18 | -6.45 | 26.99 | 6.07 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| VERA | Vera Therapeutics, Inc. | $40.79 | 2.86B | — | — | — | — | -8.67 | 4.29 | — | -6.55 | -12.48 | 4.29 | 0.00% | — | — | -50.71% | 1508.68% | -43.10% | 0.13 | — | 13.64 | 13.37 | 0.93 | 6945.00% | — | 7820.00% | -9.31% | -4.51 | 1156.04% | 0.00% | 0.00% | 9.22% | -6.21 | -8.10 | — | 10.20 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
- CEO
- Kevin Koch
- Employees
- 117
- Beta
- 0.28
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $30.61) − 1 = — (DCF, example).